Paper Details

  1. Home
  2. Paper Details

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Author: , CairnsDavid A, CollettCorinne, CookGordon, DaviesFaith E, DraysonMark T, GargMamta, GregoryWalter M, JacksonGraham H, JennerMatthew W, JonesJohn R, KaiserMartin F, KarunanithiKamaraj, KishoreBhuvan, LindsayJindriska, MorganGareth J, OwenRoger G, PawlynCharlotte, RussellNigel H, StrihaAlina, WaterhouseAnna, WilliamsCathy D, WilsonJamie N

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Multiple myeloma is a complex cancer with many different forms, suggesting that multiple treatments might be needed to achieve a good response and improve outcomes. This study examined the effectiveness of intensifying treatment for newly diagnosed myeloma by adding additional chemotherapy (cyclophosphamide, bortezomib, and dexamethasone, CVD) to standard treatment (immunomodulatory medications) in patients who had a less-than-ideal response to the initial therapy.
Paper Details　
Original Abstract of the Article :
Multiple myeloma has been shown to have substantial clonal heterogeneity, suggesting that agents with different mechanisms of action might be required to induce deep responses and improve outcomes. Such agents could be given in combination or in sequence on the basis of previous response. We aimed t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043012/

データ提供：米国国立医学図書館（NLM）

Multiple Myeloma Treatment: A Tailored Approach for Optimal Outcomes

Multiple myeloma, a type of blood cancer, presents a complex challenge for medical professionals. This study investigates the effectiveness of a response-adapted intensification treatment strategy for newly diagnosed multiple myeloma patients. Think of this approach as tailoring a camel's saddle to its specific needs, ensuring a comfortable and efficient journey through the desert of illness.

A Personalized Approach to Cancer Treatment

The researchers compared a response-adapted intensification regimen with a standard treatment approach. The results, like a map leading to a hidden oasis, suggest that a personalized approach, where treatment intensity is adjusted based on individual response, can lead to better outcomes. The study found that patients who received response-adapted intensification treatment had a deeper response to therapy and potentially better long-term survival.

Empowering Patients with Personalized Treatment

This study highlights the importance of tailoring treatment plans to individual patients. Just as a camel needs different resources and strategies to navigate a challenging desert, each multiple myeloma patient requires a unique approach to treatment. This approach recognizes the heterogeneity of cancer and allows for more precise and effective interventions.

Dr.Camel's Conclusion

This research emphasizes the importance of personalized medicine in the fight against cancer. By understanding the unique needs and responses of each patient, we can develop tailored treatment plans that maximize effectiveness and improve outcomes. It's like navigating the vast desert with a customized map and a reliable guide, leading to a destination of better health and well-being.

Date :
  1. Date Completed 2019-12-09
  2. Date Revised 2020-03-09
Further Info :

Pubmed ID

31624047

DOI: Digital Object Identifier

PMC7043012

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.